Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.

This drug, initially developed for cancer treatment, inhibits the MEK protein, which is overactivated in the cells of children with Noonan syndrome. It is this overactivation that causes pathological ...

Discover a study that used the Skindex-29 assessment to evaluate emotional wellbeing during selumetinib cycles.